Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Exoribonuclease 1 (ERI1) is an evolutionarily conserved 3'-5' exoribonuclease of the DEDDh family that catalyzes the trimming of 3' overhangs in structured RNA substrates, most notably the 3' ends of histone mRNAs and 5.8S ribosomal RNA, and also regulates small RNA turnover such as siRNA and microRNA. It is involved in both the maturation of ribosomal RNA and the regulated degradation of histone mRNAs following DNA replication, contributing to gene silencing, chromatin regulation, and proper cell-cycle progression. ERI1 also modulates RNA interference pathways, limiting or fine-tuning siRNA responses in multiple organisms. Dysregulation or mutation of ERI1 is associated with human genetic diseases (such as spondyloepimetaphyseal dysplasia), but no drug interactions or direct cancer links are well described at present.
3'-5' exoribonucleolytic degradation of RNA substrates (e.g., histone mRNAs, siRNAs, 5.8S rRNA)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Exoribonuclease 1 (ERI1).